ArticleClinical case reports2025
Ceftazidime-Induced Agranulocytosis: A Case Report.
Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most common adverse events associated with ceftazidime include hypersensitivity reactions, gastrointestinal disturbances, and transient abnormal liver function tests, whereas neutropenia is a rare complication. We present a case of ceftazidime-induced agranulocytosis in an 89-year-old Chinese woman who presented with right upper quadrant abdominal pain, nausea, and vomiting. Imaging confirmed choledocholithiasis, cholecystitis, and hepatic cysts, and laboratory tests revealed elevated inflammatory markers. Treatment with intravenous ceftazidime initially improved her symptoms and inflammatory markers; however, severe neutropenia subsequently developed, progressing to agranulocytosis. After excluding other potential causes, ceftazidime was discontinued, and granulocyte colony-stimulating factor (G-CSF) was administered, leading to hematological recovery. This case underscores that ceftazidime, albeit rarely, can cause severe drug-induced agranulocytosis. Clinicians should consider this possibility in cases of unexplained cytopenia, as prompt drug cessation and G-CSF therapy may facilitate timely hematological recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.